Biomarker Services (Luminex/Mescoscale)
Pharmacelsus supports the entire process of preclinical drug development: pharmacokinetics, pharmacodynamics, toxicology, in order to predict the risk of harmful reactions and help you to choose the most suitable candidate for clinical trials.
Using leading-edge multi-array technologies we offer multiplex high-throughput detection, quantification and characterization of Biomarkers (cytokines, hormones, enzymes) and Biopharmaceuticals (e.g. monoclonal antibodies) in different biological matrices from pre-clinical (non-GLP/GLP) as well as clinical studies (GCLP).
These technologies require only small sample volumes, while it doesn‘t mater if it has its origin in in-vitro or in-vivo sources. They allow multiple readouts on a single sample with high sensitivity and reliability.
www.gba-group.com/en/pharma/preclinical-services
Kontakt:
Pharmacelsus GmbH
Science Park 2
66123 Saarbrücken
Phone: +49 681 3946 75-10
info@pharmacelsus.com
Universitätsmedizin Magdeburg/Sarah Kossmann
Robert Hoffie
by the Society of Nuclear Medicine (Buck AK, Grigoleit GU, Kraus SK, Schirbel A, Heinsch M, Dreher N, Higuchi T, Lapa C, Hänscheid H, Samnick S, Einsele H, Serfling SE, Werner RA. C-X-C Motif Chemokine Receptor 4-Targeted Radioligand Therapy in Patients with Advanced T-Cell Lymphoma. J Nucl Med. 2022), Uniklinikum Würzburg